Keywords
fever
dyspnea
mortality
Niamey
How to Cite
Abstract
Introduction :
since December 2019, the world has been confronted with a serious contemporary crisis which is Covid-19, Niger has not been spared. The aim was to study the epidemiological, clinical, therapeutic and evolutionary characteristics of patients hospitalised for Covid-19.
Material and methods :
This was a cross-sectional study with retrospective collection for descriptive purposes of patients hospitalised for Covid-19 at the National Hôspital Amirou Boubacar Diallo (HNABD) in Niamey, Niger, over a period of 14 months (from 20 March 2020 to 03 May 2021).
Results :
A total of 115 (34.1%) patients were included out of 337 suspected cases. The mean age was 49.3 ±16 years, with males predominating (82.6%). The patients were mainly refugees (42.6%). In 21.7% of cases, patients were in contact with a suspected/confirmed case. 41.7% (n=48) of patients had at least one comorbidity, and arterial hypertension was found in 25.2% of cases. Fever, cough and dyspnoea were the clinical signs encountered in 44.4%, 38.3% and 33% of cases respectively. In 43.5% (n=50) of cases, patients were at a benign stage. Of the 25 (21.7%) scans performed, the extension of the CT lesions was severe in 48% (n=12) of cases. The combination of hydroxychloroquine and azithromycin was used in 97.4% of cases. Mortality was 8.70%. According to the odds ratios (OR), there was a significant reduction in the chances of cure as the severity of the disease increased (severe vs moderate: OR=0.22; critical vs moderate: OR=0.05).
Conclusion :
Comorbidities and severity of symptoms were factors in the severity of the disease.
References
1. Zhu N, Zhang D, Wang W, Li X, Yang B, 1104B Song J, et al. A novel Coronavirus from patients with pneumonia in China. N Engl J Med. 2020; 382(8):727-33.
2. Fu Y, Cheng Y, Wu Y. Understanding 1105B SARS-CoV-2-mediated inflammatory reponses: from mechanisms to potential therapeutic tools. Virol Sin .2020; 35:266-71.
3. Diawara A, Aminou M, Idrissa E, Adamou 1106B F, Adehossi E, Anya B, et al. Comorbidité COVID-19 et maladies chroniques à l’Hôpital General de Niamey au Niger. Rev Epidemiol sante publique .2022; 70(3) :S210-1.
4. Amankaye Mahaman R : Aspects 1107B épidémiologiques et cliniques de la COVID-19 chez les personnes âgées de plus de 60 ans à Niamey.Thèse Med. FSSNiamey. 2021, n°3467/11/03/2021,135p.
5. Sortiraparis. Coronavirus dans le monde. 1108B En ligne Consulté le 16/07/2022 ; disponible sur : https : //www.sortiraparis.com/actualites/coronav irus/articles/212134-coronavirus-dans-lemonde
6. COVID-19 : Prise en charge clinique. 1109B Orientations évolutives. WHO/2019 nCoV/clinical/2021.1
7. Ministère de la santé publique du Niger. 1110B Directive nationale de prise en charge des cas de maladie à coronavirus Disease 2019 (COVID-19). 2021. Page 7-15
8. Marchetta S, Lambermont B, Massion P, 1111B Rousseau AF, Layios N, Robinet S, et al . La première vague de la COVID-19 aux soins intensifs. Rev Med Liège. 2020 ; 75S(1) :18-
9. Bougadoum M, Koumek P, Aitbatahar S, 1112B Amro L. Pandémie COVID-19 dans la région du Maghreb .Profil épidémiologique, clinique,biologique, radiologique et évolutif des patients hospitalisés à l’hôpital Arrazi , CHU de Marrakech .Revue des Maladies respiratoires . 2021 ; 13(1) : 109-110.
10. Zabeirou AB : Aspects épidémiologique de 1113B la COVID-19 pendant la première vague à l’Hôpital General de Reference de Niamey. Thèse Med. FSS-Niamey, 2021, n°3560/28/7/2021 ,115p.
11. Grasseli G, Zangrillo A, Zanella A, 1114B Antonelli M, Cereda D, Coluccello A, et al. Baseline Characteristics and outcomes of 1591 patients infected with Sars-cov-2 admitted to ICUs of Lombardy region, Italy. JAMA. 2020; 323(16):1574-81
12. Hardy EJL, Flori P. Spécificités 1115B épidémiologiques de la COVID-19 en Afrique : préoccupation de santé publique actuelle ou future? . Ann Pharm Fr. 2020; 79(2) :216‐26
13. De Greef J, Pothen L, Yildiz H, Poncin W, 1116B Reychler G, Brilot S, et al . COVID-19: infection par le virus SARS-CoV-2.La Revue Louvain Médical. 2020 ; 139(6) : 290-301.
14. Richardson S, Hirsch JS, Narasimhan M, 1117B Crawford JM, McGinn T, Davidson KW, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area. JAMA. 2020 ; 323(20) :2052-59
15. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, 1118B He JX, et al.Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med .2020; 382(18):1708-20.
16. Ketfi A, Chabati O, Chemali S, Mahjoub M, 1119B Gharnaout M, Touahri R, et al. Profil clinique, biologique et radiologique des patients algériens hospitalisés pour C0VID19 : données préliminaires. Pan Afr Med J. 2020; 35(2):77.
17. Wang M, Cao R, Yang L, Liu J, Xu M, Shi Z, 1120B et al . Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro.Cell Research. 2020; 30(3):269-71.
18. Yao X, Ye F, Zhang M, Cui C, Huang B, Niu 1121B P, et al.In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis .2020; 71(15):732-39
19. Gao J, Tian Z, Yang X.Breakthrough: 1122B Chloroquine phosphate has shown apparent efficacy in treatment of COVID19 associated pneumonia in clinical studies. BioSci Trends .2020;14(1):72-3.
20. Gautret P, Lagier JC, Parola P, Hoang VT, 1123B Meddeb L, Mailhe M, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an openlabel non-randomized clinical trial. Int J Antimicrob Agents .2020 ; 56(1) :105949.
21. Gautret P, Lagier JC, Parola P, Hoang VT, 1124B Meddeb L, Sevestre J, et al . Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: A pilot observational study. Travel Med Infect Dis. 2020; 34:101663
22. Stawicki S, Jeanmonod R, Miller AC , 1125B Paladino L, Gaieski DF, Yaffee AQ, et al . The 2019-2020 Novel Coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2) Pandemic: A Joint American College of Academic International Medicine-World Academic Council of Emergency Medicine Multidisciplinary COVID-19 Working Group Consensus Paper. J Glob Infect Dis .2020; 12(2):47-93.
23. Wu C, Chen X, Cai Y, Xia J, Zhou X, Xu S 1126B ,et al . Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan China. JAMA Intern Med. 2020;180 (7):934-43
24. Plaçais L, Richier Q. COVID-19: 1127B caractéristiques cliniques, biologiques et radiologiques chez l’adulte, la femme enceinte et l’enfant. Une mise au point au cœur de la pandémie. Rev Med Intern .2020; 41(5):308-18. 1128B
Metrics
Downloads
This work is licensed under a Creative Commons Attribution 4.0 International License.
Copyright (c) 2026 S Halidou Moussa, M Gagara Issoufou, I Hamidou, A Cheikh Aboubacar, A Ramadan, D Maizoumbou, M Ouédraogo